Abstract:Abstract Background The growing discipline of structural systems pharmacology is applied prospectively in this study to predict pharmacological outcomes of antibacterial compounds in Escherichia coli K12. This work builds upon previously established methods for structural prediction of ligand binding pockets on protein molecules and utilizes and expands upon the previously developed genome scale model of metabolism integrated with protein structures (GEM-PRO) for E. coli , structurally accounting for protein complexes. Carefully selected case studies are demonstrated to display the potential for this structural systems pharmacology framework in discovery and development of antibacterial compounds. Results The prediction framework for antibacterial activity of compounds was validated for a control set of well-studied compounds, recapitulating experimentally-determined protein binding interactions and deleterious growth phenotypes resulting from these interactions. The antibacterial activity of fosfomycin, sulfathiazole, and trimethoprim were accurately predicted, and as a negative control glucose was found to have no predicted antibacterial activity. Previously uncharacterized mechanisms of action were predicted for compounds with known antibacterial properties, including (1-hydroxyheptane-1,1-diyl)bis(phosphonic acid) and cholesteryl oleate. Five candidate inhibitors were predicted for a desirable target protein without any known inhibitors, tryptophan synthase β subunit (TrpB). In addition to the predictions presented, this effort also included significant expansion of the previously developed GEM-PRO to account for physiological assemblies of protein complex structures with activities included in the E. coli K12 metabolic network. Conclusions The structural systems pharmacology framework presented in this study was shown to be effective in the prediction of molecular mechanisms of antibacterial compounds. The study provides a promising proof of principle for such an approach to antibacterial development and raises specific molecular and systemic hypotheses about antibacterials that are amenable to experimental testing. This framework, and perhaps also the specific predictions of antibacterials, is extensible to developing antibacterial treatments for pathogenic E. coli and other bacterial pathogens.

Imaging‐based profiling for elucidation of antibacterial mechanisms of action

Imaging-based profiling for elucidation of antibacterial mechanisms of action

Spectroscopic techniques for elucidating the mechanism of action of antibacterial agents

Classification of antimicrobial mechanism of action using dynamic bacterial morphology imaging

Molecular imaging of bacterial biofilms-a systematic review

Advances in Image-Guided Drug Delivery for Antibacterial Therapy

High-throughput time-resolved morphology screening in bacteria reveals phenotypic responses to antibiotics

Evaluation of novel compounds as anti-bacterial or anti-virulence agents

Application Prospects of FTIR Spectroscopy and CLSM to Monitor the Drugs Interaction with Bacteria Cells Localized in Macrophages for Diagnosis and Treatment Control of Respiratory Diseases

Antibacterial mechanisms identified through structural systems pharmacology

Real-Time Biosynthetic Reaction Monitoring Informs the Mechanism of Action of Antibiotics

Activity-based protein profiling in drug/pesticide discovery: Recent advances in target identification of antibacterial compounds

Rapid screening of bacteriostatic and bactericidal antimicrobial agents against Escherichia coli by combining machine learning (artificial intelligence) and UV-VIS spectroscopy

Mass spectrometry-based metabolomics for the investigation of antibiotic-bacterial interactions

Metabolic Fingerprinting with Fourier-Transform Infrared (FTIR) Spectroscopy: Towards a High-Throughput Screening Assay for Antibiotic Discovery and Mechanism-of-Action Elucidation

Photochemical Strategies toward Precision Targeting against Multidrug-Resistant Bacterial Infections

Bioactive Phyto-Compounds with Antimicrobial Effects and AI: Results of a Desk Research Study

A machine learning approach-based array sensor for rapidly predicting the mechanisms of action of antibacterial compounds

Targeting bacterial growth in biofilm conditions: rational design of novel inhibitors to mitigate clinical and food contamination using QSAR

Engineering molecular theranostic probes for antibaterial therapy

Profiling cell envelope-antibiotic interactions reveals vulnerabilities to β-lactams in a multidrug-resistant bacterium